Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908235 | 0.86 | RXRA (0.74) | RXRARXRBRXRGRARARARB | |
| SCHEMBL13716998 | 0.83 | RXRA (0.50) | RXRARXRBRXRGRARARARB | |
| SCHEMBL10355823 | 0.83 | CYP3A4 (0.43) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL27804194 | 0.82 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL3982018 | 0.82 | RXRA (0.72) | RXRARXRBRXRGRARARARB | |
| SCHEMBL24055801 | 0.78 | RXRA (0.46) | RXRARXRBRXRGRARARARB | |
| SCHEMBL24055013 | 0.77 | RXRA (0.65) | RXRARXRBRXRGRARARARB | |
| SCHEMBL9185753 | 0.75 | CYP3A4 (0.50) | RXRATDP1MAPTCA1CA2 | |
| SCHEMBL9746239 | 0.74 | PTPN11 (0.48) | RXRARARARARBRARGCA1 | |
| SCHEMBL11677735 | 0.74 | RXRA (0.68) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885RXRB 5/4885RXRG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.